Zacks Small Cap Research – DYAI: First Product Sales Are Modest
By John Vandermosten, CFA NASDAQ: DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic Applied BioSolutions, Inc. (NASDAQ: DYAI) announced 3Q:26 results on November 12th, 2026, and hosted a conference call that day. The company recorded its first direct commercial product sales, primarily recombinant transferrin and DNase I, a milestone marking the shift from a research-driven company to a commercial one.








